<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ann Am Thorac Soc</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann Am Thorac Soc</journal-id>
<journal-id journal-id-type="publisher-id">AnnalsATS</journal-id>
<journal-title-group>
<journal-title>Annals of the American Thoracic Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">2329-6933</issn>
<issn pub-type="epub">2325-6621</issn>
<publisher>
<publisher-name>American Thoracic Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27925785</article-id>
<article-id pub-id-type="pmc">5291498</article-id>
<article-id pub-id-type="publisher-manuscript">201605-402OT</article-id>
<article-id pub-id-type="doi">10.1513/AnnalsATS.201605-402OT</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>AnnalsATS Supplement</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Accelerating Scientific Advancement for Pediatric Rare Lung Disease Research. Report from a National Institutes of Health–NHLBI Workshop, September 3 and 4, 2015</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Young</surname>
<given-names>Lisa R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trapnell</surname>
<given-names>Bruce C.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mandl</surname>
<given-names>Kenneth D.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Swarr</surname>
<given-names>Daniel T.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wambach</surname>
<given-names>Jennifer A.</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Blaisdell</surname>
<given-names>Carol J.</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup></label>Department of Pediatrics, Medicine, and Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee</aff>
<aff id="aff2"><label><sup>2</sup></label>Department of Medicine, and</aff>
<aff id="aff3"><label><sup>3</sup></label>Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, Ohio</aff>
<aff id="aff4"><label><sup>4</sup></label>Department of Pediatrics, and</aff>
<aff id="aff5"><label><sup>5</sup></label>Department of Biomedical Informatics, Harvard Medical School, Computational Health Informatics Program, Boston Children’s Hospital, Boston, Massachusetts</aff>
<aff id="aff6"><label><sup>6</sup></label>Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</aff>
<aff id="aff7"><label><sup>7</sup></label>Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; and</aff>
<aff id="aff8"><label><sup>8</sup></label>Division of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence and requests for reprints should be addressed to Carol J. Blaisdell, M.D., Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Two Rockledge Centre, Suite 10042, 6701 Rockledge Drive, Bethesda, MD 20892-7952. E-mail: <email xlink:href="carol.blaisdell@nih.gov">carol.blaisdell@nih.gov</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2016</year>
<!--string-date: December 2016-->
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>12</month>
<year>2016</year>
<!--string-date: December 2016-->
</pub-date>
<volume>13</volume>
<issue>12</issue>
<fpage>385</fpage>
<lpage>393</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>10</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 by the American Thoracic Society</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="AnnalsATS.201605-402OT.pdf"></self-uri>
<abstract>
<p>Pediatric rare lung disease (PRLD) is a term that refers to a heterogeneous group of rare disorders in children. In recent years, this field has experienced significant progress marked by scientific discoveries, multicenter and interdisciplinary collaborations, and efforts of patient advocates. Although genetic mechanisms underlie many PRLDs, pathogenesis remains uncertain for many of these disorders. Furthermore, epidemiology and natural history are insufficiently defined, and therapies are limited. To develop strategies to accelerate scientific advancement for PRLD research, the NHLBI of the National Institutes of Health convened a strategic planning workshop on September 3 and 4, 2015. The workshop brought together a group of scientific experts, intramural and extramural investigators, and advocacy groups with the following objectives: (<italic>1</italic>) to discuss the current state of PRLD research; (<italic>2</italic>) to identify scientific gaps and barriers to increasing research and improving outcomes for PRLDs; (<italic>3</italic>) to identify technologies, tools, and reagents that could be leveraged to accelerate advancement of research in this field; and (<italic>4</italic>) to develop priorities for research aimed at improving patient outcomes and quality of life. This report summarizes the workshop discussion and provides specific recommendations to guide future research in PRLD.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>rare disease</kwd>
<kwd>genomics</kwd>
<kwd>discovery</kwd>
<kwd>outcomes</kwd>
<kwd>children</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="2"></table-count>
<page-count count="9"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>